Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Q: Protein kinases (PKs) and lipid kinases (LKs) are good choices for targets of signal transduction therapy as these enzymes are involved in signaling pathways, and are often related to the pathogenesis of lymphoid malignancies. The attractiveness of PKs and LKs as drug able targets is enhanced by the fact that they are enzymes whose biological activity can be turned off by drugs that block their catalytic site. In the last few years small molecular kinase inhibitors (KIs) have been synthesized and become available for preclinical studies and clinical trials. The first KI, introduced into clinical practice in 1998, was imatinib mesylate, which became the first choice drug in chronic myeloid leukemia. More recently, several KIs have been developed to target the proximal B-cell receptor (BCR) signaling pathway including spleen tyrosine kinase inhibitor (Fostamatinib) and Bruton's tyrosine kinase inhibitors (Ibrutinib, AVL-263). These agents are currently evaluated in early clinical trials in chronic lymphocytic leukemia (CLL) and other diseases. Cyclin-dependent kinase (Cdk) inhibitors, flavopiridol (alvocidib), BMS-387032 (SNS-032), sunitinib and sorafenib are currently under evaluation in clinical trials for relapsed/refractory CLL. Multi-tyrosine kinase inhibitors including vandetanib (ZD6474) bosutinib (SKI-606), TKI258 (CHIR-258), pazopanib (GW786034) and axitinib (AG013736) have been also developed for the treatment of lymphoid malignancies. Phosphatidylinositol 3-kinases (PI3K ) are a family of lipid kinases that mediate signals from cell surface receptors. CAL-101 (GS-1101) is an oral PI3K-specific inhibitor which has shown preclinical and clinical activity against CLL. This article summarizes recent achievements in the mechanism of action, pharmacological properties and clinical activity and toxicity of PK and LK inhibitors in CLL.

A: What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?
****
Q: There are records of fingerprints taken many centuries ago. The ancient Babylonians pressed the tips of their fingerprints into clay to record business trade. The Chinese used ink-on-paper finger impressions for business. However, fingerprinting wasn't used as a method for identifying criminals until the 19th century. In 1858, Sir William Herschel was working as an official of the Hooghly district in Jungipoor, India.In order to reduce fraud , he had people living in the district record their fingerprints when signing business documents. A few years later, Scottish doctor Henry Faulds was working in Japan when he discovered fingerprints left by artists on ancient pieces of clay.This finding inspired him to begin investigating fingerprints.In 1880, Faulds wrote to his cousin, the famous naturalist Charles Darwin, and asked for help with developing a fingerprint classification system.Darwin refused, but sent the letter to his cousin, Sir Francis Gallon, who was an eugenicist . Gallon began collecting fingerprints and eventually gathered some 8, 000 different samples to analyze. In 1892, he published a book called "Fingerprints", in which he outlined a fingerprint classification system--the first existence. Around the same time, Juan Vucetich, a police officer in Buenos Aires, Argentina, was developing his own version of a fingerprinting system.In 1892, Vucetich was called in to assist with the investigation of the two boys murdered in Necoche, a village near Buenos Aires. Their mother, Francisca Rojas, accused a neighbour named Velasquez. But when Vucetich compared the fingerprints found at the murder scene to those of both Velasquez and Rojas, _ matched Rojas' exactly.She admitted her crime. This was the first time fingerprints had been used in a criminal investigation.Vucetich called his system comparative dactyloscopy . It's still used in many Spanish-speaking countries. Sir Edward Henry, in charge of the Metropolitan Police of London, soon became interested in using fingerprints to catch criminals. In 1896, he added to Gallon's technique, creating his own classification system, the Henry Classification System. It is the primary method of fingerprint classification throughout most of the world.

A: Who first came up with the idea of creating a fingerprint classification system?
****
Q: Chediak-Higashi syndrome (CHS) is a rare multiorgan disease entity with autosomal recessive inheritance characterized by oculocutaneous albinism, bleeding tendency, recurrent bacterial infections and various neurological symptoms. Intracellular vesicle formation is deficient, resulting in giant granules in many cells, e.g. giant melanosomes in the melanocytes. Diagnosis has been based on morphological examination of peripheral blood and bone marrow, with giant granules seen in cells of the myeloid lineage and in lymphocytes. The ultimate diagnostic test is to look for a mutated LYST gene. Most patients develop an accelerated phase of the disease with deposition of lymphohistiocytes in the liver, spleen, lymph nodes and bone marrow, resulting in hepatosplenomegaly, bone marrow infiltration and haemophagocytosis. Peripheral blood neutropenia becomes more profound as anaemia and thrombocytopenia develop. Most patients succumb before the age of 10 years. Four patients with CHS are described, one of whom is a long-term survivor after successful allogeneic bone marrow transplantation, two succumbed during the accelerated phase and one is living with a chronic form of the disease. Allogeneic bone marrow transplantation from an HLA-matched sibling is the therapy of choice and should be performed early. If there is no matched family donor, an unrelated donor or a placental blood graft is a good alternative. The clinical picture of CHS is heterogeneous and therapeutic decisions need to be made on an individual basis.

A:
Which mutated gene causes the Chédiak–Higashi Syndrome?
****